Ysios Capital has announced the participation in the financing round of the US company Mineralys Therapeutics, for a total  amount of $118 million. This is the tenth investment of Ysios Capital's third fund, Ysios BioFund III, and the first in the US. For this operation, Ysios has joined an international investment syndicate led by RA Capital Management and Andera Partners. The fund manager, a member of CataloniaBio &  HealthTech, expects to close two more new investments before the end of  the year.

Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-HTN, for patients with uncontrolled hypertension. The company anticipates releasing the top-line results of Target-HTN later this year.

"Hypertension continues to be the leading cause of cardiovascular and renal diseases, but there has been little innovation in this area in the last five years. Mineralys' innovative approach has the potential to significantly improve the quality of life and life expectancy of millions of people affected by this disease," said Joël Jean-Mairet, Managing Partner of Ysios Capital. "The exceptional syndicate of top-tier US and European investors supporting Mineralys is a clear demonstration of the company's strength and clinical data," he adds.

In the context of this transaction, Olivier Litzka, PhD, partner at Andera Partners, and Derek DiRocco, partner at RA Capital Management, will join the Board of Directors of Mineralys. Joël Jean-Mairet, Managing Partner at Ysios Capital,  will join the Board as an Observer.

Ysios Capital, a venture capital manager focused on life sciences companies, has offices in San Sebastian and Barcelona. Founded in 2008, it has over €400 million in assets under management through its three funds.

Photo: Joël Jean-Mairet, Managing Partner of Ysios Capital